Mission Statement, Vision, & Core Values (2024) of Sunshine Biopharma, Inc. (SBFM)

An Overview of Sunshine Biopharma, Inc. (SBFM)

General Summary of Sunshine Biopharma, Inc. (SBFM)

Sunshine Biopharma, Inc. (SBFM) is a biopharmaceutical company focused on the development of innovative drugs to treat various diseases, particularly in oncology and infectious diseases. The company operates through its wholly owned subsidiary, Nora Pharma, which holds numerous Drug Identification Numbers (DINs) issued by Health Canada. As of 2024, Sunshine Biopharma has expanded its product line to include several over-the-counter (OTC) products such as Essential•9, Essential Calcium-Vitamin D, L-Citrulline, and Taurine, which have been authorized for sale by Health Canada.

As of 2024, the company reported sales of approximately $25.28 million for the nine months ended September 30, representing a significant increase from $16.41 million during the same period in 2023. This growth is attributed to enhanced marketing and sales efforts, particularly by Nora Pharma, which has successfully penetrated new regional markets.

Company's Financial Performance in the Latest Financial Reports

In the nine months ended September 30, 2024, Sunshine Biopharma recorded revenues of $25,279,291, marking an increase of 54% from $16,412,586 in the same period the previous year. The gross profit for this period was $7,576,745, up from $5,771,125 in 2023. The direct costs associated with generating these revenues were $17,702,546, equating to 70% of total revenue, compared to 65% in 2023.

For the three months ended September 30, 2024, the company achieved sales of $8,435,178, compared to $5,957,668 in the prior year, indicating a 42% increase. The gross profit for this quarter was $2,866,151, compared to $1,990,256 in the same quarter of 2023.

Despite the increase in sales, the company reported an operational loss of $3,774,399 for the nine months ended September 30, 2024, slightly higher than the loss of $3,598,078 in the same period of 2023. The net loss for the nine-month period was $2,975,904 (or $13.61 per share) versus a net loss of $3,256,020 (or $265.71 per share) in 2023. As of September 30, 2024, cash and cash equivalents stood at $12,206,655.

Introduction to Company as a Leader in the Industry

Sunshine Biopharma, Inc. has established itself as a key player in the biopharmaceutical industry through its commitment to developing innovative therapeutic solutions. The company’s strategic focus on oncology and infectious diseases, combined with its successful OTC product line, positions it favorably in the competitive landscape of healthcare. Notably, Sunshine Biopharma's growth trajectory reflected in its financial performance showcases its potential for future success. Investors and stakeholders are encouraged to explore further to understand the factors contributing to Sunshine Biopharma's achievements and its ongoing commitment to advancing healthcare solutions.

Mission Statement of Sunshine Biopharma, Inc. (SBFM)

Mission Statement of Sunshine Biopharma, Inc. (SBFM)

Sunshine Biopharma, Inc. (SBFM) is committed to developing and providing high-quality pharmaceutical products. The company’s mission statement emphasizes its focus on innovation, integrity, and the delivery of life-saving treatments in various therapeutic areas, particularly in oncology and antiviral medications. This mission is vital as it guides the company's strategic direction, ensuring that all operational efforts align with its overarching goal of improving patient outcomes.

Core Component 1: Innovation

Innovation is at the heart of Sunshine Biopharma’s mission. The company actively engages in research and development to create novel therapies. For instance, Sunshine Biopharma is developing K1.1, an mRNA-based treatment aimed at liver cancer, and SBFM-PL4, a protease inhibitor targeting SARS Coronavirus infections. As of September 30, 2024, the company reported a gross profit of $7,576,745 for the nine-month period, reflecting a 54% increase in revenue compared to the same period in 2023.

Core Component 2: Integrity

Integrity is a core value that Sunshine Biopharma upholds in all its business practices. The company ensures transparency in its operations, maintaining ethical standards in drug development and marketing. The increase in general and administrative expenses to $11,351,144 for the nine months ended September 30, 2024, highlights the company's commitment to compliance and operational excellence. This includes investments in legal and accounting services to enhance governance and regulatory adherence.

Core Component 3: Patient-Centric Approach

Sunshine Biopharma’s mission is deeply rooted in a patient-centric approach, aiming to improve the quality of life for patients through accessible healthcare solutions. The company operates two subsidiaries, Nora Pharma and Sunshine Biopharma Canada, which collectively provide a broad portfolio of generic prescription drugs and over-the-counter products. As of September 30, 2024, the company had cash and cash equivalents amounting to $12,206,655, ensuring it can sustain its operations while focusing on expanding its product offerings.

Sunshine Biopharma's mission statement serves as a foundational element guiding its strategic initiatives, ensuring that the company remains committed to its core values of innovation, integrity, and patient-centric care.

Vision Statement of Sunshine Biopharma, Inc. (SBFM)

Vision Statement Overview

The vision statement of Sunshine Biopharma, Inc. (SBFM) is focused on becoming a leader in the pharmaceutical industry, particularly in the development of innovative therapies for cancer and other serious diseases. The company aims to leverage its unique capabilities and technologies to improve the lives of patients globally.

Innovation and Development

Sunshine Biopharma emphasizes its commitment to research and development (R&D) as a core component of its vision. In 2024, the company reported a total of $784,630 spent on R&D for the nine-month period ending September 30, compared to $1,039,502 for the same period in 2023, indicating a strategic focus on refining and optimizing its developmental processes.

Market Expansion

Part of SBFM's vision involves expanding its market presence. The company generated revenues of $25,279,291 for the nine months ended September 30, 2024, up from $16,412,586 during the same period in 2023, marking a 54% increase. This growth is attributed to enhanced marketing and sales efforts through its subsidiary, Nora Pharma.

Patient-Centric Approach

Sunshine Biopharma's vision includes a strong focus on patient needs. The development of prescription drugs and over-the-counter products, such as Essential•9 and Essential Calcium-Vitamin D, aligns with their goal to provide effective therapies that cater to specific health concerns.

Financial Stability and Growth

Financial health is integral to SBFM's vision. As of September 30, 2024, the company reported total assets of $30,056,816, with shareholders' equity standing at $25,039,312. The increase in capital paid in excess of par value also reflects the company's efforts to secure financial backing for its growth initiatives.

Commitment to Compliance and Quality

Sunshine Biopharma’s vision includes a commitment to maintaining high standards of compliance and quality in all its products. As of September 30, 2024, the company held 152 Drug Identification Numbers (DINs) issued by Health Canada, which are necessary for the marketing of its prescription drugs.

Strategic Partnerships and Collaborations

To further its vision, Sunshine Biopharma is actively seeking strategic partnerships that enhance its research capabilities and market reach. Such collaborations are essential for advancing its innovative therapies and achieving sustainable growth.

Core Values of Sunshine Biopharma, Inc. (SBFM)

Integrity

Integrity is the cornerstone of Sunshine Biopharma, Inc.'s operations. It signifies the commitment to ethical practices and transparency in all dealings.

In 2024, Sunshine Biopharma has actively demonstrated integrity through compliance with regulatory requirements, maintaining an open dialogue with stakeholders, and ensuring that all marketing materials for its products are truthful and not misleading. The company's adherence to Health Canada regulations is evident as it holds 152 Drug Identification Numbers (DINs) for prescription drugs, reflecting its commitment to adhere to high standards of safety and efficacy.

Innovation

Innovation drives Sunshine Biopharma's growth and product development strategy. The company is dedicated to advancing its research and development efforts to introduce new therapies.

As of 2024, Sunshine Biopharma is developing multiple proprietary drugs, including K1.1, targeting liver cancer, and SBFM-PL4, a protease inhibitor for SARS Coronavirus. The investment in research is underscored by the increase in research and development expenses, which amounted to approximately $784,630 for the nine months ended September 30, 2024.

Collaboration

Collaboration is vital for Sunshine Biopharma to achieve its goals and enhance its market position. The company fosters partnerships that enhance its capabilities and expand its reach.

In 2024, Sunshine Biopharma's collaboration with Nora Pharma has resulted in significant revenue growth, with revenues reaching $25,279,291 for the nine months ended September 30, 2024, a 54% increase from the previous year. This collaboration has allowed the company to leverage shared resources and expertise, particularly in marketing and sales efforts, to penetrate new markets effectively.

Accountability

Accountability at Sunshine Biopharma ensures that all employees and management are responsible for their actions, fostering a culture of trust and reliability.

The company has implemented robust internal controls and regular financial disclosures, highlighting its commitment to accountability. For the nine months ended September 30, 2024, Sunshine Biopharma reported a net loss of $2,975,904, reflecting its ongoing challenges while maintaining transparency with shareholders. The detailed financial reporting illustrates the company’s dedication to keeping stakeholders informed about its operational performance and financial health.

Community Engagement

Community engagement is a core value that reflects Sunshine Biopharma's commitment to making a positive impact beyond its business operations.

In 2024, the company has taken steps to enhance its community engagement by supporting health initiatives and educational programs related to its therapeutic areas, particularly in oncology. This not only strengthens its brand but also aligns with its mission to provide life-saving medicines and contribute to public health.

Updated on 16 Nov 2024

Resources:

1. Sunshine Biopharma, Inc. (SBFM) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Sunshine Biopharma, Inc. (SBFM)' financial performance, including balance sheets, income statements, and cash flow statements.
2. SEC Filings – View Sunshine Biopharma, Inc. (SBFM)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.